NLSP
Closed
Nls Pharmaceutics Ag
2.86
-0.04 (-1.38%)
Last Update: 01 Jul 2025 23:17:00
Yesterday: 2.9
Day's Range: 2.76 - 3.0289
Send
sign up or login to leave a comment!
When Written:
1.5
NLS Pharmaceutics AG is a Swiss-based biopharmaceutical company that specializes in developing innovative treatments for central nervous system (CNS) disorders. The company's focus is on developing drugs that target the underlying mechanisms of CNS diseases such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
NLS Pharmaceutics AG was founded in 2015 and is headquartered in Zurich, Switzerland. The company's lead product candidate is Quilience®, a novel treatment for insomnia that is currently in Phase 2 clinical trials. Quilience® is a combination of two FDA-approved drugs that have been repurposed for the treatment of insomnia.
NLS Pharmaceutics AG has a team of experienced pharmaceutical executives and scientists who are dedicated to developing innovative treatments for CNS disorders. The company has partnerships with leading academic institutions and research organizations to advance its drug development programs.
Overall, NLS Pharmaceutics AG is a promising biopharmaceutical company that is focused on developing innovative treatments for CNS disorders. Its lead product candidate, Quilience®, has the potential to be a game-changer in the treatment of insomnia.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
NLS Pharmaceutics AG was founded in 2015 and is headquartered in Zurich, Switzerland. The company's lead product candidate is Quilience®, a novel treatment for insomnia that is currently in Phase 2 clinical trials. Quilience® is a combination of two FDA-approved drugs that have been repurposed for the treatment of insomnia.
NLS Pharmaceutics AG has a team of experienced pharmaceutical executives and scientists who are dedicated to developing innovative treatments for CNS disorders. The company has partnerships with leading academic institutions and research organizations to advance its drug development programs.
Overall, NLS Pharmaceutics AG is a promising biopharmaceutical company that is focused on developing innovative treatments for CNS disorders. Its lead product candidate, Quilience®, has the potential to be a game-changer in the treatment of insomnia.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








